Content
@
0 reply
0 recast
0 reaction
christin
@christin
I've helped dozens of pharmaceutical companies educate healthcare providers about diseases, the latest treatment options, and the harrowing journey patients go through. You would think these are topics that medical schools cover, but healthcare is evolving so quickly that continual medical education is often provided by drug companies. Education is especially vital for rare diseases. They are not top-of-mind for healthcare professionals because they're by definition uncommon. I remember working on marketing a drug for idiopathic pulmonary fibrosis, a rare lung disease. Since treatments available only slowed down progression and are not curative, doctors often opted to "watch and wait." This robbed patients of years of their lives in a silent way. Both my company and the competitor spent millions on medical education, bc the true competitor wasn't between the companies, it was against the inertia of "watch and wait." Yet inertia can be conquered: by educating customers, we empowered them to take action.
18 replies
8 recasts
41 reactions
Omar
@dromar.eth
Such a great read and the pace of medical evolution is a great point. Enjoyed it and couldn’t agree more. Especially for newer treatments, the adoption rate is abysmal and the wait and watch approach is non-productive. I wish more of the education was available for rare disease and diseases targeted at PCPs rather than specialist. Having had extensive Hem/Onc experience from working at an Oncology Center and also a TB clinic, most pharmaceutical reps focused heavily on specialists while giving little focus on PCPs. PCPs are usually the biggest advocates of their patients understanding both the medical and social impact of their illness and many times can put the foot down in socialists pursuing a treatment when they would not otherwise.
0 reply
0 recast
0 reaction
